IP Library Granted Patent US 10,000,523
Granted Patent B2
US 10,000,523 · App. 15/782,628 · Granted Jun 19, 2018

β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N

Inventors: Jean-Pierre Sommadossi (Boston, MA); Adel Moussa (Burlington, MA)
Assignee: Atea Pharmaceuticals, Inc.
C07H19/207A61K31/7076C07H19/16C07H19/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,000,523
App. No.
15/782,628
Granted
Jun 19, 2018
Kind
B2
Abstract

A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Claims (32)

1. A pharmaceutical composition comprising an anti-HCV effective amount of a compound of the formula:

in a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , comprising an effective amount of a compound of the formula:

3. The pharmaceutical composition of claim 1 , comprising an effective amount of a compound of the formula:

4. The pharmaceutical composition of claim 1 , in a dosage form.

5. The pharmaceutical composition of claim 4 , in an oral dosage form.

6. The pharmaceutical composition of claim 5 , in a tablet.

7. The pharmaceutical composition of claim 5 , in a capsule.

8. The pharmaceutical composition of claim 2 , in a dosage form.

9. The pharmaceutical composition of claim 8 , in an oral dosage form.

10. The pharmaceutical composition of claim 9 , in a tablet.

11. The pharmaceutical composition of claim 9 , in a capsule.

12. The pharmaceutical composition of claim 3 , in a dosage form.

13. The pharmaceutical composition of claim 12 , in an oral dosage form.

14. The pharmaceutical composition of claim 13 , in a tablet.

15. The pharmaceutical composition of claim 13 , in a capsule.

16. A pharmaceutical composition comprising an anti-HCV effective amount of a compound of the formula:

in a pharmaceutically acceptable carrier.

17. The pharmaceutical composition of claim 16 , comprising an effective amount of a compound of the formula:

18. The pharmaceutical composition of claim 16 , comprising an effective amount of a compound of the formula:

19. The pharmaceutical composition of claim 16 , in a dosage form.

20. The pharmaceutical composition of claim 19 , in an oral dosage form.

21. The pharmaceutical composition of claim 20 , in a tablet.

22. The pharmaceutical composition of claim 20 , in a capsule.

23. The pharmaceutical composition of claim 17 , in a dosage form.

24. The pharmaceutical composition of claim 23 , in an oral dosage form.

25. The pharmaceutical composition of claim 24 , in a tablet.

26. The pharmaceutical composition of claim 24 , in a capsule.

27. The pharmaceutical composition of claim 18 , in a dosage form.

28. The pharmaceutical composition of claim 27 , in an oral dosage form.

29. The pharmaceutical composition of claim 28 , in a tablet.

30. The pharmaceutical composition of claim 28 , in a capsule.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2018
From: SOMMADOSSI, JEAN-PIERRE; MOUSSA, ADEL
To: ATEA PHARMACEUTICALS, INC.
Reel/Frame 044804/0809 →
Continuity (5)
Continuation 15063461 · Mar 7, 2016
Provisional Application 62276597 · Jan 8, 2016
Provisional Application 62253958 · Nov 11, 2015
Provisional Application 62129319 · Mar 6, 2015
Related Publication 20180030081A1 · Feb 1, 2018
Cited By (3)
US 12,226,429 US 12,458,656 US 12,551,499